NEW YORK (GenomeWeb) – Santa Cruz, California-based Two Pore Guys said today that it is collaborating with oncologists at the University of California, San Francisco to develop a liquid biopsy assay. The UCSF team plans to evaluate Two Pore Guys' handheld nanopore platform for detecting circulating tumor DNA, and specifically, for detecting a KRAS mutation from blood and urine samples.

Andrew Ko, a professor of hematology and oncology and gastrointestinal cancer specialist at the UCSF Helen Diller Family Comprehensive Cancer Center, will lead the study.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Sep
20

This webinar will discuss how next-generation sequencing (NGS) can help clinical research labs and pathologists save time, money, and samples compared to single-analyte oncology research assays.

Sep
21

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

Sep
27

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.